药物治疗患者的认知障碍,抑郁症缓解和抗胆固醇活性较低
Naoto Yoshinari1, Hitoshi Maeshima1, Kentaro Shimizu1
1Juntendo University Mood Disorder Project (JUMP), Department of Psychiatry, Juntendo Koshigaya Hospital, 560 Fukuroyama, Koshigaya City, Saitama 343-0046, Japan; Department of Psychiatry, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Journal of affective disorders
|September 25, 2024
概括
缓解性严重抑郁症 (MDD) 患者的血清抗胆固醇活性 (SAA) 与认知功能障碍有关. 较高的SAA水平与记忆和认知测试的表现较差相关,这表明MDD的持续作用.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 大型抑郁症 (MDD) 缓解与认知功能障碍有关.
- 抗胆固醇活性与认知障碍有关,但程度尚不清楚.
研究的目的:
- 测量MDD缓解的患者的血清抗胆固醇活性 (SAA).
- 检查SAA水平和MDD患者缓解后认知功能之间的关系.
主要方法:
- 招募了49名缓解的MDD患者和165名健康对照.
- 施用Stroop测试,维克斯勒记忆尺度修订 (逻辑记忆和视觉复制子测试).
- 基于SAA水平 (高于或低于量化极限) 和健康对照的认知评分进行比较.
主要成果:
- 与对照组相比,SAA阳性患者在所有测试中表现明显差 (p < 0.001).
- SAA阴性患者的视觉复制分数明显低于对照组 (p = 0.024).
- SAA水平显著影响了逻辑记忆得分 (p = 0.015).
结论:
- 抗抑郁药的抗胆固醇作用可能对缓解的MDD的认知功能产生不利影响.
- 在缓解的MDD中,认知障碍可能会由于疾病本身而持续存在.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
201
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
201
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
107
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
107
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
635
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
635
Psychosis: Goals of Pharmacotherapy
110
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
110
Parkinson's Disease: Treatment
235
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
235


